Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Piramal Pharma Limited ( (IN:PPLPHARMA) ) just unveiled an update.
Piramal Pharma’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, and will publish these in line with SEBI disclosure norms. The company also appointed Maneesh Sharma as Company Secretary and Compliance Officer effective 29 April 2026, signaling a refresh in its governance infrastructure.
In a broader board-level reset, the company cleared the re-appointment of Executive Director and Chairperson Nandini Piramal for three years from 1 April 2027 and Executive Director Peter DeYoung for three years from 6 October 2026, both subject to shareholder approval. Independent directors Sridhar Gorthi and Peter Stevenson were also approved for second five-year terms from 30 March 2027, reinforcing continuity and regulatory-compliant oversight on the board as the company navigates its next growth phase.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company engaged in manufacturing and providing a range of pharma products and services. The company operates in the broader healthcare and life sciences industry, with its shares listed on BSE and NSE under the symbol PPLPHARMA, and is governed by SEBI’s listing regulations as a public entity.
Average Trading Volume: 217,020
Technical Sentiment Signal: Hold
Current Market Cap: 219.9B INR
Find detailed analytics on PPLPHARMA stock on TipRanks’ Stock Analysis page.